Strategies for the identification of novel inhibitors of deubiquitinating enzymes

  • 格式:pdf
  • 大小:96.02 KB
  • 文档页数:5

828BiochemicalSocietyTransactions(2008)Volume36,part5

Strategiesfortheidentificationofnovelinhibitors

ofdeubiquitinatingenzymes

SethJ.Goldenberg1,JeffreyL.McDermott,TauseefR.Butt,MichaelR.MatternandBenjaminNicholson

ProgenraInc.,271AGreatValleyParkway,Malvern,PA19355,U.S.A.

Abstract

DysregulationoftheUPS(ubiquitin–proteasomesystem)hasbeenimplicatedinawiderangeofpathologies

includingcancer,neurodegenerationandviralinfection.Inhibitingtheproteasomehasbeenshowntobean

effectivetherapeuticstrategyinhumans;yettoxicitywiththistargetremainshigh.DUBs(deubiquitinating

enzymes)representanalternativetargetintheUPSwithlowpredictedtoxicity.Currently,therearenoDUB

inhibitorsthathavebeenusedclinically.Toaddressthissituation,Progenrahasdevelopedanovelassay

tomeasuretheproteolyticcleavageofUb(ubiquitin)orUBL(Ub-likeprotein)conjugatessuchasSUMO

(smallUb-relatedmodifier),NEDD8(neural-precursor-cell-expressed,developmentallydown-regulated8)

orISG15(interferon-stimulatedgene15)byisopeptidases.Inthisreview,currentplatformsfordetecting

DUBinhibitorsarediscussedandtheadvantagesanddisadvantagesoftheapproachesareunderlined.

Introduction

TheconjugationofUb(ubiquitin)andUBLs(Ub-like

proteins)isanimportantregulatorymechanismthatis

widespreadinmanybiologicalprocesses[1].Theassorted

diseasesassociatedwiththesepathwaysmakethepathway

enzymesparticularlyinterestingfortherapeutictargets.The

UPS(Ub–proteasomesystem)hasbeenvalidatedfollow-

ingtheapprovaloftheproteasomeinhibitorBortezomib

forthetreatmentofmultiplemyeloma;however,significant

toxicitieswereseenduringclinicaltrials,suggestingtheneed

formoreselectivetargets[2].Ub-andUBL-isopeptidases

representauniquesetofdrugtargetsintheUPSthatare

responsibleforremovingUbandUBLs,suchasSUMO

(smallUb-relatedmodifier),NEDD8(neural-precursor-

cell-expressed,developmentallydown-regulated8)and

ISG15(interferon-stimulatedgene15),fromtargetproteins,

thusaffectingthetargets’fate[3].Todeveloptherapeutic

agentsthattargetisopeptidases,wedevelopedareadily

quantifiablenovelisopeptidaseassayplatformthatissuitable

forHTS(high-throughputscreening).Theassayplatform

consistsofUborUBLfusedtothereporterenzymePLA2(phospholipaseA2).IsopeptidaseactivityreleasesPLA2that

cleavesitssubstrate,generatingasignalthatislinearwith

isopeptidaseconcentrationandisabletodiscriminateDUB

(deubiquitinatingenzyme),deSUMOylase,deNEDDylase

Keywords:deISGylase,deNEDDylase,deSUMOylase,deubiquitinatingenzyme(DUB),high-throughputscreening(HTS),isopeptidase,smallubiquitin-relatedmodifier(SUMO).Abbreviationsused:DUB,deubiquitinatingenzyme;FRET,fluorescenceresonanceenergytransfer;HTS,high-throughputscreening;ISG15,interferon-stimulatedgene15;NEDD8,neural-precursor-cell-expressed,developmentallydown-regulated8;PLA2,phospholipaseA2;RING,reallyinterestingnewgene;SCF,Skp1/cullin/F-box;Skp,S-phasekinase-associatedprotein;Ub,ubiquitin;SUMO,smallUb-relatedmodifier;TRAF,tumour-necrosis-factor-receptor-associatedfactor;TR-FRET,time-resolvedFRET;Ub-AMC,Ub-7-amino-4-methylcoumarin;UBL,Ub-likeprotein;UBP/USP,Ub-specificproteases;ULP,UBL-specificprotease;UPS,Ub–proteasomesystem.1Towhomcorrespondenceshouldbeaddressed(emailGoldenberg@progenra.com).anddeISGylaseactivities.Theassaycanbesuccessfully

employedtoscreenforinhibitorsofisopeptidases.

TherapeutictargetsintheUPS

TheapprovaloftheproteasomeinhibitorBortezomib

(Velcade)forthetreatmentofmultiplemyelomavalidated

thetargetingoftheUPSforthetreatmentofcancer[4].

However,extendedtreatmentwithBortezomibisassociated

withtoxicityanddrugresistance,limitingitsefficacy[2].

Incontrast,therapeuticstrategiesthattargetspecificaspects

oftheUPSupstreamoftheproteasomewouldbepredicted

tohavelowertoxicity.Whileactivatingenzymes(E1)and

conjugatingenzymes(E2)areupstreamoftheproteasome,

onemustbeawareoftheconsequencesoftargetingthem,as

disruptionoftheE1leadstocell-cyclearrest[5]andE2shave

beenshowntoberequiredfordevelopment[6].Targeting

theUb-activatingenzymemaybepredictedtoaffecttoo

manycellularfunctionsforittobetoleratedbynormalcells;

yettargetingtheNEDD8-activatingenzymeforinhibition

hasbeenreportedtobesuccessfulinpreclinicalstudies[7].

Themechanismofactionismostlikelythroughinactivation

ofthecullin-basedE3ligases,manyofwhichplayacrucial

roleincell-cyclecheckpointswhosedisruptionwouldhave

amoreimmediateeffectonrapidlydividingcancercells.

E3ligases,withonlyalimitednumberofsubstrates,

representattractivedrugtargetsintheUPS.Oneofthemost

interestingE3targetsisSCF[Skp(S-phasekinase-associated

protein)1/cullin/F-box].TheSCFcomplexconsistsofmany

variableF-boxadaptorproteinseachofwhichtargetonlya

fewsubstratesforubiquitination[8].Twotherapeuticallyrel-

evantF-boxproteinsareSkp2[9]andβ-TRCP(β-transducin

repeat-containingprotein)[10],whichplaykeyrolesin